Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: The OLMEBEST study

Clinical Drug Investigation

Volumn 27, Issue 8, 2007, Pages 545-558

  Barrios, Vivencio ^a   Boccanelli, Alessandro ^b   Ewald, Silke ^c   Girerd, Xavier ^d   Heagerty, Anthony ^e   Krzesinski, Jean Marie ^f   Lins, Robert ^g   Rodicio, José ^h   Stefenelli, Thomas ⁱ   Woittiez, Arend ^j   Böhm, Michael ^k  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b Azienda Complesso O   (Italy)

^c DAIICHI SANKYO CO   (Japan)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g Stuivenberg General Hospital   (Belgium)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ Kaiserin Elisabeth Spital der Stadt Wien   (Austria)

^j TWENTEBORG HOSPITAL   (Netherlands)

^k SAARLAND UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; OLMESARTAN;

ACUTE HEART FAILURE; ACUTE RESPIRATORY FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BORDERLINE HYPERTENSION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; LIVER DYSFUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; SUDDEN DEATH; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES;

EID: 34547308715     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727080-00003     Document Type: Article

References (31)

1. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560-72
2. Guidelines Committee. 2003 European Society of Hypertension: European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21 (6): 1011-53
3. Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21 (11): 1983-92
4. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275 (20): 1571-6
5. Hajjar I, Kotchen JM, Kotchen TA. Hypertension: trends in prevalence, incidence, and control. Annu Rev Public Health 2006; 27: 465-90
6. Cheung BM, Ong KL, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002. J Clin Hypertens (Greenwich) 2006; 8 (2): 93-8
7. Erdine S. How well is hypertension controlled in Europe? Update on hypertension management. European Society of Hypertension Scientific Newsletter 2000; 1 (3): 1-2
8. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43 (1): 10-7
9. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861-9
10. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359 (9311): 995-1003
11. Volpe M, Ruilope LM, McInnes GT, et al. Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens 2005; 19 (5): 331-9
12. Birkenhäger WH, de Leeuw PW. Non-peptide angiotensin type I receptor antagonists in treatment of hypertension. J Hypertens 1999; 17 (7): 873-81
13. Mancia G, Seravalle G, Grassi G. Tolerability and treatment stratecompliance with angiotensin II receptor antagonists. Am J Hypertens 2003; 16 (12): 1066-73
14. Mizuno M, Sada T, Ikeda M, et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995; 285 (2): 181-8
15. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3 (5): 283-91
16. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002; 16 Suppl. 2: S24-8
17. Brunner HR, Laeis P. Clinical efficacy of olmesartan medoxomil. J Hypertens Suppl 2003; 21 (2): S43-6
18. Smith DHG, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5 (1): 41-50
19. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Invest 2006; 26 (4): 185-93
20. Stumpe KO. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther 2004; 26 Suppl. A: A33-7
21. Warner GT, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62 (9): 1345-53
22. National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care: partial update. London: Royal College of Physicians, 2006
23. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001; 87 Suppl.: 37C-43C
24. Giles TD, Robinson TD. Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertension. Am J Hypertens 2004; 17 (8): 690-5
25. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17 (3): 252-9
26. Sellin L, Stegbauer J, Laeis P, et al. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005; 23 (11): 2083-92
27. Chrysant SG, Chrysant GS. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin Pharmacother 2004; 5 (3): 657-67
28. Neutel JM, Smith DH, Weber MA, et al. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004; 6 (4): 168-74
29. Black HR. The evolution of low-dose diuretic therapy: the lessons from clinical trials. Am J Med 1996; 101 (3A): 47S-52S
30. Weir MR, Flack JM, Applegate WB. Tolerability, safety, and quality of life and hypertensive therapy: the case for low-dose diuretics. Am J Med 1996; 101 (3A): 83S-92S
31. Owens P, Kelly L, Nallen R, et al. Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide: a randomized controlled trial. J Hypertens 2000; 18 (3): 339-45